Safety and Incidence of Cardiovascular Events in Chinese Patients with Acute Coronary Syndrome Treated with Ticagrelor: the 12-Month, Phase IV, Multicenter, Single-Arm DAYU Study

PURPOSE: Ticagrelor is an orally administered, reversibly binding, direct-acting P2Y(12) receptor antagonist previously evaluated in several phase III trials. This phase IV, multicenter, single-arm trial assessed the safety and incidence of cardiovascular (CV) events with ticagrelor in Chinese patie...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cardiovasc Drugs Ther
Päätekijät: Gao, Runlin, Wu, Yongjian, Liu, Hengliang, Su, Guohai, Yuan, Zuyi, Zhang, Aidong, Wang, Yong, Wang, Zhirong, Wang, Yan, Zhang, Huanyi, Zheng, Yang, Liu, Lei, Shen, Lijun, Leonsson-Zachrisson, Maria, Han, Yaling
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer US 2018
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5843700/
https://ncbi.nlm.nih.gov/pubmed/29488142
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10557-018-6772-3
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia